Clinical Trial Update: Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs [Phase 2]

View source ↗

Summary

Phase 2 trial update for oral rigosertib in low-risk myelodysplastic syndromes patients refractory to ESAs.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Rigosertib (rigosertib)

Snippet

Sponsor: Traws Pharma, Inc. | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED